{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:29:33Z","timestamp":1762342173793},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurochir"],"DOI":"10.1007\/s00701-023-05858-2","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T19:02:35Z","timestamp":1699297355000},"page":"3637-3641","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Moyamoya disease presenting with symptomatic ischemic stroke during new-generation tyrosine kinase inhibitor treatment: two illustrative cases"],"prefix":"10.1007","volume":"165","author":[{"given":"Hideki","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Io","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"5858_CR1","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/ccr3.729","volume":"4","author":"R Alshiekh-Nasany","year":"2016","unstructured":"Alshiekh-Nasany R, Zidan A, Martinez C (2016) Extensive intracranial arterial stenosis in conjunction with the use of tyrosine kinase inhibitor nilotinib. Clin Case Rep 4:1184\u20131186","journal-title":"Clin Case Rep"},{"key":"5858_CR2","first-page":"e28","volume":"10","author":"CJ Chen","year":"2018","unstructured":"Chen CJ, Sorace BJ, Shakeri A, Park MS, Southerland AM, Worrall BB, Kalani MYS (2018) Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement. J Neuro Interventional Surg 10:e28","journal-title":"J Neuro Interventional Surg"},{"key":"5858_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ajh.23442","volume":"88","author":"EA Coon","year":"2013","unstructured":"Coon EA, Zalewski NL, Hoffman EM, Tefferi A, Flemming KD (2013) Nilotinib treatment-associated cerebrovascular disease and stroke. Am J Hematol 88:534\u2013535","journal-title":"Am J Hematol"},{"key":"5858_CR4","doi-asserted-by":"publisher","first-page":"804","DOI":"10.7887\/jcns.30.804","volume":"30","author":"S Fujiwara","year":"2021","unstructured":"Fujiwara S, Fukumoto S, Miyazaki Y, Aso K, Ichikawa H, Onoue S, Iwata S, Ohue S (2021) A case of multiple arterial stenoses due to long-term nilotinib exposure. Jpn J Neurosurg 30:804\u2013810","journal-title":"Jpn J Neurosurg"},{"key":"5858_CR5","first-page":"411","volume":"32","author":"JB Gomez-Galvan","year":"2017","unstructured":"Gomez-Galvan JB, Borrego S, Tovar N, Llull L (2017) Nilotinib as a risk factor for ischemic stroke: a series of three cases. Neurol Engl Ed 32:411\u2013413","journal-title":"Neurol Engl Ed"},{"issue":"4","key":"5858_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"Global Burden of Disease Cancer Collaboration","year":"2017","unstructured":"Global Burden of Disease Cancer Collaboration (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1995\u20132015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524\u2013548","journal-title":"JAMA Oncol"},{"issue":"1","key":"5858_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","volume":"16","author":"H Haguet","year":"2017","unstructured":"Haguet H, Douxfil J, Mullier F, Chatelain C, Graux C, Dogne J (2017) Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf 16(1):5\u201312","journal-title":"Expert Opin Drug Saf"},{"key":"5858_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00701-021-05043-3","volume":"164","author":"A Hirayama","year":"2022","unstructured":"Hirayama A, Sorimachi T, Yokota K, Shigematsu H, Srivatanakul K, Matsumae M (2022) New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases. Acta Neurochir 164:1623\u20131626","journal-title":"Acta Neurochir"},{"key":"5858_CR9","first-page":"2","volume":"72","author":"NGL Jager","year":"2014","unstructured":"Jager NGL, Stuurman FE, Baars JW, Opdam FL (2014) Cerebrovascular events during nilotinib treatment. Neth J Med 72:2","journal-title":"Neth J Med"},{"key":"5858_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2176\/jns-nmc.2022-0072","volume":"62","author":"S Kuroda","year":"2022","unstructured":"Kuroda S, Fujimura M, Takahashi J, Kataoka H, Ogasawara K, Iwama T, Tominaga T, Miyamoto S (2022) Diagnostic criteria for moyamoya disease - 2021 revised version. Neurol Med Chir (Tokyo) 62:307\u2013312","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"5858_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S1474-4422(08)70240-0","volume":"7","author":"S Kuroda","year":"2008","unstructured":"Kuroda S, Houkin K (2008) Moyamoya disease: current concepts and future perspectives. Lancet Neurol 7:1056\u20131066","journal-title":"Lancet Neurol"},{"key":"5858_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","volume":"40","author":"A Manouchehri","year":"2020","unstructured":"Manouchehri A, Kanu E, Mauro MJ, Aday AW, Linder JR, Moslehi J (2020) Tyrosine kinase inhibitors in leukemia and cardiovascular events: form mechanism to patient care. Arterioscler Thromb Vasc Biol 40:301\u2013308","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5858_CR13","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger (2015) Tyrosine kinase inhibitors-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 33:4210\u20134218","journal-title":"J Clin Oncol"},{"key":"5858_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.5692\/clinicalneurol.cn-001222","volume":"59","author":"A Nakaya","year":"2019","unstructured":"Nakaya A, Ebitani M, Monzen T, Nagano T, Saito F, Yaoita Y (2019) A case of recurrent cerebral infarction during treatment of oral tyrosine kinase inhibitor for chronic myelogenous leukemia. Rinsho Shinkeigaku 59:418\u2013424","journal-title":"Rinsho Shinkeigaku"},{"key":"5858_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","volume":"17","author":"T O\u2019Hare","year":"2011","unstructured":"O\u2019Hare T, Deininger MWN, Eide CA, Clackson T, Druker BJ (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant philadelphia chromosome-positive leukemia. Clin Cancer Res 17:212\u2013221","journal-title":"Clin Cancer Res"},{"key":"5858_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1177\/1591019917710810","volume":"23","author":"T Ozaki","year":"2017","unstructured":"Ozaki T, Nakamura H, Izutsu N, Masaie H, Ishikawa J, Kinoshita M (2017) Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia. Interv Neuroradiol 23:527\u2013530","journal-title":"Interv Neuroradiol"},{"key":"5858_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2176\/jns-nmc.2022-0298","volume":"10","author":"Y Rai","year":"2023","unstructured":"Rai Y, Hara T (2023) Tyrosine kinase inhibitor-associated cerebral arterial occlusive disease treated with high-flow bypass surgery: a case report. NMC Case Rep J 10:61\u201366","journal-title":"NMC Case Rep J"},{"key":"5858_CR18","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.06.043","volume":"26","author":"Y Shinya","year":"2017","unstructured":"Shinya Y, Miyawaki S, Imai H, Hongo H, Ono H, Takenobu A, Nakatomi H, Teraoka A, Saito N (2017) Genetic analysis of ring finger protein 213 (RNF213) c.14576G > A in intracranial atherosclerosis of the anterior and posterior circulations. J Stroke Cerebrovasc Dis 26:2638\u20132644","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"5858_CR19","first-page":"239","volume":"10","author":"K Suzuki","year":"2019","unstructured":"Suzuki K, Yamamoto J, Kakeda S, Takamatsu S, Miyaoka R, Kitagawa T, Saito T, Nakano Y, Nishizawa S (2019) Vessel wall magnetic resonance imaging findings and surgical treatment in nilotinib-associated cerebrovascular disease: a case report. Mol Clin Oncol 10:239\u2013243","journal-title":"Mol Clin Oncol"},{"key":"5858_CR20","doi-asserted-by":"publisher","first-page":"116577","DOI":"10.1016\/j.jns.2019.116577","volume":"408","author":"M Uemura","year":"2020","unstructured":"Uemura M, Kanazawa M, Yamagishi T, Nagai T, Takahashi M, Koide S, Tada M, Simbo J, Isami A, Makino K, Masuko M, Nikkuni K, Okamoto K, Igarashi S, Morita K, Onodera O (2020) Role of RNF213 p.4810K variant in the development of intracranial arterial disease in patients treated with nilotinib. J Neurol Sci 408:116577","journal-title":"J Neurol Sci"}],"container-title":["Acta Neurochirurgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-023-05858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00701-023-05858-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00701-023-05858-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:21:30Z","timestamp":1703168490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00701-023-05858-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["5858"],"URL":"https:\/\/doi.org\/10.1007\/s00701-023-05858-2","relation":{},"ISSN":["0942-0940"],"issn-type":[{"type":"electronic","value":"0942-0940"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript is written in accordance with the 1964 WMA Declaration of Helsinki. All the procedures being performed and treatment received were part of routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patients about the publication of the case details and any associated images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}